Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

作者：Digenio Andres^*; Dunbar Richard L; Alexander Veronica J; Hompesch Marcus; Morrow Linda; Lee Richard G; Graham Mark J; Hughes Steven G; Yu Rosie; Singleton Walter; Baker Brenda F; Bhanot Sanjay; Crooke Rosanne M

来源：Diabetes Care, 2016, 39(8): 1408-1415.

DOI：10.2337/dc16-0126

OBJECTIVETo determine the effects of volanesorsen (ISIS 304801), a second-generation 2'-O-methoxyethyl chimeric antisense inhibitor of apolipoprotein (apo)C-III, on triglyceride (TG) levels and insulin resistance in patients with type 2 diabetes.RESEARCH DESIGN AND METHODSA randomized, double-blind, placebo-controlled trial was performed in 15 adult patients with type 2 diabetes (HbA(1c) >7.5% [58 mmol/mol]) and hypertriglyceridemia (TG >200 and <500 mg/dL). Patients were randomized 2:1 to receive volanesorsen 300 mg or placebo for a total of 15 subcutaneous weekly doses. Glucose handling and insulin sensitivity were measured before and after treatment using a two-step hyperinsulinemic-euglycemic clamp procedure.RESULTSTreatment with volanesorsen significantly reduced plasma apoC-III (-88%, P = 0.02) and TG (-69%, P = 0.02) levels and raised HDL cholesterol (HDL-C) (42%, P = 0.03) compared with placebo. These changes were accompanied by a 57% improvement in whole-body insulin sensitivity (P < 0.001). Importantly, we found a strong relationship between enhanced insulin sensitivity and both plasma apoC-III (r = -0.61, P = 0.03) and TG (r = -0.68, P = 0.01) suppression. Improved insulin sensitivity was sufficient to significantly lower glycated albumin (-1.7%, P = 0.034) and fructosamine (-38.7 mol/L, P = 0.045) at the end of dosing and HbA(1c) (-0.44% [-4.9 mmol/mol], P = 0.025) 3 months postdosing.CONCLUSIONSVolanesorsen reduced plasma apoC-III and TG while raising HDL-C levels. Importantly, glucose disposal, insulin sensitivity, and integrative markers of diabetes also improved in these patients after short-term treatment.

• 出版日期2016-8